B dot Medical Inc. (Headquarters: Edogawa-ku, Tokyo; CEO: Takuji Furukawa; “B dot Medical”) announced today that it has successfully closed its Series B2 financing round, raising JPY 1.3 billion. The funds were secured through a third-party allocation of shares utilizing the J-Ships system (Scheme for Stock Transfer for Professional Investors), on October 2, 2025.
This latest funding brings B dot Medical’s total capital raised since its founding in March 2017 to JPY 6.8 billion.
Background and Purpose of the Funding
B dot Medical is a medical device startup dedicated to the manufacturing and sales of its ultra-compact proton therapy system. Our mission, “Proton for Everyone”, drives us to invent innovative technologies to achieve a compact, efficient and high-performance proton beam cancer treatment system. Our goal is to create a society where high-quality proton therapy is accessible to everyone globally.
The capital raised in this round will be strategically used to accelerate on-site demonstration projects for the actual system installation and to drive our global market expansion.
A Statement from Takuji Furukawa, CEO of B dot Medical
“We are pleased to have successfully completed our Series B2 funding round, raising JPY 1.3 billion. We extend our gratitude to all our investors for their support. The cumulative JPY 6.8 billion raised since our founding is a strong affirmation that the market recognizes the potential and unique value of our ultra-compact proton therapy system. Our technology fundamentally breaks down the barriers of size and cost that have traditionally limited the spread of proton therapy. We are committed to pursuing our mission, ‘Proton for Everyone,’ to contribute to global cancer treatment as quickly as possible.”
